Research and Development Expense of LIFECORE BIOMEDICAL, INC. \DE\ from 30 May 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
LIFECORE BIOMEDICAL, INC. \DE\ quarterly and annual Research and Development Expense in USD history and change rate from 30 May 2010 to 30 Sep 2025.
  • LIFECORE BIOMEDICAL, INC. \DE\ Research and Development Expense for the quarter ending 30 Sep 2025 was $1,963,000, a 10% decline year-over-year.
  • LIFECORE BIOMEDICAL, INC. \DE\ Research and Development Expense for the twelve months ending 30 Sep 2025 was $8,035,000, a 6.7% decline year-over-year.
  • LIFECORE BIOMEDICAL, INC. \DE\ annual Research and Development Expense for 2024 was $8,258,000, a 3.7% decline from 2023.
  • LIFECORE BIOMEDICAL, INC. \DE\ annual Research and Development Expense for 2023 was $8,575,000, a 1.8% decline from 2022.
  • LIFECORE BIOMEDICAL, INC. \DE\ annual Research and Development Expense for 2022 was $8,736,000, a 11% increase from 2021.
Source SEC data
View on sec.gov
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)

LIFECORE BIOMEDICAL, INC. \DE\ Quarterly Research and Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,035,000 $1,963,000 -$223,000 -10% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2026 Q1
Q2 2025 $8,258,000 $2,103,000 -$58,000 -2.7% 24 Feb 2025 25 May 2025 10-K 07 Aug 2025 2025 FY
Q1 2025 $8,316,000 $2,045,000 -$125,000 -5.8% 25 Nov 2024 23 Feb 2025 10-Q 03 Apr 2025 2025 Q3
Q4 2024 $8,441,000 $1,924,000 -$174,000 -8.3% 26 Aug 2024 24 Nov 2024 10-Q 02 Jan 2025 2025 Q2
Q3 2024 $8,615,000 $2,186,000 +$40,000 +1.9% 27 May 2024 25 Aug 2024 10-Q 06 Nov 2025 2026 Q1
Q2 2024 $8,575,000 $2,161,000 +$47,000 +2.2% 26 Feb 2024 26 May 2024 10-K 07 Aug 2025 2025 FY
Q1 2024 $8,528,000 $2,170,000 -$64,000 -2.9% 27 Nov 2023 25 Feb 2024 10-Q 03 Apr 2025 2025 Q3
Q4 2023 $8,592,000 $2,098,000 -$79,000 -3.6% 28 Aug 2023 26 Nov 2023 10-Q 02 Jan 2025 2025 Q2
Q3 2023 $8,671,000 $2,146,000 -$65,000 -2.9% 29 May 2023 27 Aug 2023 10-Q 04 Oct 2024 2025 Q1
Q2 2023 $8,736,000 $2,114,000 -$102,000 -4.6% 27 Feb 2023 28 May 2023 10-K 26 Aug 2024 2024 FY
Q1 2023 $8,838,000 $2,234,000 -$20,000 -0.89% 28 Nov 2022 26 Feb 2023 10-Q 09 Aug 2024 2024 Q3
Q4 2022 $8,858,000 $2,177,000 +$497,000 +30% 29 Aug 2022 27 Nov 2022 10-Q 09 Aug 2024 2024 Q2
Q3 2022 $8,361,000 $2,211,000 +$522,000 +31% 30 May 2022 28 Aug 2022 10-Q 09 Aug 2024 2024 Q1
Q2 2022 $7,839,000 $2,216,000 +$499,000 +29% 28 Feb 2022 29 May 2022 10-K 26 Aug 2024 2024 FY
Q1 2022 $7,340,000 $2,254,000 +$617,000 +38% 29 Nov 2021 27 Feb 2022 10-K 20 Mar 2024 2023 FY
Q4 2021 $6,723,000 $1,680,000 +$89,000 +5.6% 30 Aug 2021 28 Nov 2021 10-K 20 Mar 2024 2023 FY
Q3 2021 $6,634,000 $1,689,000 -$50,000 -2.9% 31 May 2021 29 Aug 2021 10-K 20 Mar 2024 2023 FY
Q2 2021 $6,684,000 $1,717,000 +$2,525,000 01 Mar 2021 30 May 2021 10-K 20 Mar 2024 2023 FY
Q1 2021 $4,159,000 $1,637,000 -$1,110,000 -40% 30 Nov 2020 28 Feb 2021 10-K 20 Mar 2024 2023 FY
Q4 2020 $5,269,000 $1,591,000 -$1,231,000 -44% 31 Aug 2020 29 Nov 2020 10-K 20 Mar 2024 2023 FY
Q3 2020 $6,500,000 $1,739,000 -$1,082,000 -38% 01 Jun 2020 30 Aug 2020 10-K 20 Mar 2024 2023 FY
Q2 2020 $7,582,000 $808,000 -$4,269,000 -123% 24 Feb 2020 31 May 2020 10-K/A 16 Mar 2023 2022 FY
Q1 2020 $11,851,000 $2,747,000 +$8,000 +0.29% 25 Nov 2019 23 Feb 2020 10-Q 08 Apr 2021 2021 Q3
Q4 2019 $11,843,000 $2,822,000 +$347,000 +14% 26 Aug 2019 24 Nov 2019 10-Q 07 Jan 2021 2021 Q2
Q3 2019 $11,496,000 $2,821,000 +$30,000 +1.1% 27 May 2019 25 Aug 2019 10-Q 07 Oct 2020 2021 Q1
Q2 2019 $11,466,000 $3,461,000 -$135,000 -3.8% 25 Feb 2019 26 May 2019 10-K 29 Jul 2021 2021 FY
Q1 2019 $11,601,000 $2,739,000 -$374,000 -12% 26 Nov 2018 24 Feb 2019 10-Q 03 Apr 2020 2020 Q3
Q4 2018 $11,975,000 $2,475,000 -$897,000 -27% 27 Aug 2018 25 Nov 2018 10-Q 02 Jan 2020 2020 Q2
Q3 2018 $12,872,000 $2,791,000 +$72,000 +2.6% 28 May 2018 26 Aug 2018 10-Q 03 Oct 2019 2020 Q1
Q2 2018 $12,800,000 $3,596,000 +$40,000 +1.1% 26 Feb 2018 27 May 2018 10-K 14 Aug 2020 2020 FY
Q1 2018 $12,760,000 $3,113,000 +$1,099,000 +55% 27 Nov 2017 25 Feb 2018 10-Q 04 Apr 2019 2019 Q3
Q4 2017 $11,661,000 $3,372,000 +$1,407,000 +72% 28 Aug 2017 26 Nov 2017 10-Q 07 Jan 2019 2019 Q2
Q3 2017 $10,254,000 $2,719,000 +$781,000 +40% 29 May 2017 27 Aug 2017 10-Q 05 Oct 2018 2019 Q1
Q2 2017 $9,473,000 $3,556,000 +$1,741,000 +96% 27 Feb 2017 28 May 2017 10-K 01 Aug 2019 2019 FY
Q1 2017 $7,732,000 $2,014,000 +$119,000 +6.3% 28 Nov 2016 26 Feb 2017 10-Q 05 Apr 2018 2018 Q3
Q4 2016 $7,613,000 $1,965,000 +$322,000 +20% 29 Aug 2016 27 Nov 2016 10-Q 05 Jan 2018 2018 Q2
Q3 2016 $7,291,000 $1,938,000 +$63,000 +3.4% 30 May 2016 28 Aug 2016 10-Q 28 Sep 2017 2018 Q1
Q2 2016 $7,228,000 $1,815,000 +$202,000 +13% 29 Feb 2016 29 May 2016 10-K 09 Aug 2018 2018 FY
Q1 2016 $7,026,000 $1,895,000 +$140,000 +8% 30 Nov 2015 28 Feb 2016 10-Q 07 Apr 2017 2017 Q3
Q4 2015 $6,886,000 $1,643,000 -$182,000 -10% 31 Aug 2015 29 Nov 2015 10-Q 05 Jan 2017 2017 Q2
Q3 2015 $7,068,000 $1,875,000 +$80,000 +4.5% 01 Jun 2015 30 Aug 2015 10-Q 29 Sep 2016 2017 Q1
Q2 2015 $6,988,000 $1,613,000 -$23,000 -1.4% 02 Mar 2015 31 May 2015 10-K/A 15 Mar 2018 2017 FY
Q1 2015 $7,011,000 $1,755,000 +$32,000 +1.9% 01 Dec 2014 01 Mar 2015 10-Q 30 Mar 2016 2016 Q3
Q4 2014 $6,979,000 $1,825,000 -$94,000 -4.9% 01 Sep 2014 30 Nov 2014 10-Q 07 Jan 2016 2016 Q2
Q3 2014 $7,073,000 $1,795,000 -$131,000 -6.8% 02 Jun 2014 31 Aug 2014 10-Q 01 Oct 2015 2016 Q1
Q2 2014 $7,204,000 $1,636,000 -$1,016,000 -38% 24 Feb 2014 25 May 2014 10-K 01 Aug 2016 2016 FY
Q1 2014 $8,220,000 $1,723,000 -$602,000 -26% 25 Nov 2013 23 Feb 2014 10-Q 02 Apr 2015 2015 Q3
Q4 2013 $8,822,000 $1,919,000 -$194,000 -9.2% 26 Aug 2013 24 Nov 2013 10-Q 09 Jan 2015 2015 Q2
Q3 2013 $9,016,000 $1,926,000 -$278,000 -13% 27 May 2013 25 Aug 2013 10-Q 08 Oct 2014 2015 Q1
Q2 2013 $9,294,000 $2,652,000 +$170,000 +6.8% 25 Feb 2013 26 May 2013 10-K 31 Jul 2015 2015 FY
Q1 2013 $9,124,000 $2,325,000 -$148,000 -6% 26 Nov 2012 24 Feb 2013 10-Q 28 Mar 2014 2014 Q3
Q4 2012 $9,272,000 $2,113,000 -$224,000 -9.6% 27 Aug 2012 25 Nov 2012 10-Q 03 Jan 2014 2014 Q2
Q3 2012 $9,496,000 $2,204,000 -$129,000 -5.5% 28 May 2012 26 Aug 2012 10-Q 26 Sep 2013 2014 Q1
Q2 2012 $9,625,000 $2,482,000 -$31,000 -1.2% 27 Feb 2012 27 May 2012 10-K 01 Aug 2014 2014 FY
Q1 2012 $9,656,000 $2,473,000 +$198,000 +8.7% 28 Nov 2011 26 Feb 2012 10-Q 04 Apr 2013 2013 Q3
Q4 2011 $9,458,000 $2,337,000 +$82,000 +3.6% 29 Aug 2011 27 Nov 2011 10-Q 04 Jan 2013 2013 Q2
Q3 2011 $9,376,000 $2,333,000 +$101,000 +4.5% 30 May 2011 28 Aug 2011 10-Q/A 02 Jan 2013 2013 Q1
Q2 2011 $9,275,000 $2,513,000 28 Feb 2011 29 May 2011 10-K 07 Aug 2013 2013 FY
Q1 2011 $2,275,000 29 Nov 2010 27 Feb 2011 10-Q 28 Mar 2012 2012 Q3
Q4 2010 $2,255,000 30 Aug 2010 28 Nov 2010 10-Q 05 Jan 2012 2012 Q2
Q3 2010 $2,232,000 01 Jun 2010 29 Aug 2010 10-Q 05 Oct 2011 2012 Q1

LIFECORE BIOMEDICAL, INC. \DE\ Annual Research and Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,258,000 -$317,000 -3.7% 27 May 2024 25 May 2025 10-K 07 Aug 2025 2025 FY
2023 $8,575,000 -$161,000 -1.8% 29 May 2023 26 May 2024 10-K 07 Aug 2025 2025 FY
2022 $8,736,000 +$897,000 +11% 30 May 2022 28 May 2023 10-K 26 Aug 2024 2024 FY
2021 $7,839,000 +$1,155,000 +17% 31 May 2021 29 May 2022 10-K 26 Aug 2024 2024 FY
2020 $6,684,000 -$898,000 -12% 01 Jun 2020 30 May 2021 10-K 20 Mar 2024 2023 FY
2019 $7,582,000 -$3,884,000 -34% 27 May 2019 31 May 2020 10-K/A 16 Mar 2023 2022 FY
2018 $11,466,000 -$1,334,000 -10% 28 May 2018 26 May 2019 10-K 29 Jul 2021 2021 FY
2017 $12,800,000 +$3,327,000 +35% 29 May 2017 27 May 2018 10-K 14 Aug 2020 2020 FY
2016 $9,473,000 +$2,245,000 +31% 30 May 2016 28 May 2017 10-K 01 Aug 2019 2019 FY
2015 $7,228,000 +$240,000 +3.4% 01 Jun 2015 29 May 2016 10-K 09 Aug 2018 2018 FY
2014 $6,988,000 -$216,000 -3% 26 May 2014 31 May 2015 10-K/A 15 Mar 2018 2017 FY
2013 $7,204,000 -$2,090,000 -22% 27 May 2013 25 May 2014 10-K 01 Aug 2016 2016 FY
2012 $9,294,000 -$331,000 -3.4% 28 May 2012 26 May 2013 10-K 31 Jul 2015 2015 FY
2011 $9,625,000 +$350,000 +3.8% 30 May 2011 27 May 2012 10-K 01 Aug 2014 2014 FY
2010 $9,275,000 +$4,914,000 +113% 31 May 2010 29 May 2011 10-K 07 Aug 2013 2013 FY
2009 $4,361,000 01 Jun 2009 30 May 2010 10-K 08 Aug 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.